These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 36424890)

  • 1. SARS-CoV-2 Vaccine Strain Selection: Guidance From Influenza.
    Monto AS; Lauring AS; Martin ET
    J Infect Dis; 2022 Dec; 227(1):4-8. PubMed ID: 36424890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection - Increasing Community Access to Testing Program, United States, September-November 2022.
    Link-Gelles R; Ciesla AA; Fleming-Dutra KE; Smith ZR; Britton A; Wiegand RE; Miller JD; Accorsi EK; Schrag SJ; Verani JR; Shang N; Derado G; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(48):1526-1530. PubMed ID: 36454688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
    Link-Gelles R; Levy ME; Gaglani M; Irving SA; Stockwell M; Dascomb K; DeSilva MB; Reese SE; Liao IC; Ong TC; Grannis SJ; McEvoy C; Patel P; Klein NP; Hartmann E; Stenehjem E; Natarajan K; Naleway AL; Murthy K; Rao S; Dixon BE; Kharbanda AB; Akinseye A; Dickerson M; Lewis N; Grisel N; Han J; Barron MA; Fadel WF; Dunne MM; Goddard K; Arndorfer J; Konatham D; Valvi NR; Currey JC; Fireman B; Raiyani C; Zerbo O; Sloan-Aagard C; Ball SW; Thompson MG; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Jul; 71(29):931-939. PubMed ID: 35862287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance - VISION Network, 10 States, December 2021-August 2022.
    Britton A; Embi PJ; Levy ME; Gaglani M; DeSilva MB; Dixon BE; Dascomb K; Patel P; Schrader KE; Klein NP; Ong TC; Natarajan K; Hartmann E; Kharbanda AB; Irving SA; Dickerson M; Dunne MM; Raiyani C; Grannis SJ; Stenehjem E; Zerbo O; Rao S; Han J; Sloan-Aagard C; Griggs EP; Weber ZA; Murthy K; Fadel WF; Grisel N; McEvoy C; Lewis N; Barron MA; Nanez J; Reese SE; Mamawala M; Valvi NR; Arndorfer J; Goddard K; Yang DH; Fireman B; Ball SW; Link-Gelles R; Naleway AL; Tenforde MW
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1335-1342. PubMed ID: 36264840
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine models predict rules for updating vaccines against evolving pathogens such as SARS-CoV-2 and influenza in the context of pre-existing immunity.
    Desikan R; Linderman SL; Davis C; Zarnitsyna VI; Ahmed H; Antia R
    Front Immunol; 2022; 13():985478. PubMed ID: 36263031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Facing the Omicron variant-how well do vaccines protect against mild and severe COVID-19? Third interim analysis of a living systematic review.
    Külper-Schiek W; Piechotta V; Pilic A; Batke M; Dreveton LS; Geurts B; Koch J; Köppe S; Treskova M; Vygen-Bonnet S; Waize M; Wichmann O; Harder T
    Front Immunol; 2022; 13():940562. PubMed ID: 36091023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022.
    Surie D; Bonnell L; Adams K; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Shehu A; Frosch AP; Erickson HL; Gong MN; Mohamed A; Johnson NJ; Srinivasan V; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Rivas C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Hart KW; Swan SA; Zhu Y; DeCuir J; Tenforde MW; Patel MM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Oct; 71(42):1327-1334. PubMed ID: 36264830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
    Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
    MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
    Surie D; DeCuir J; Zhu Y; Gaglani M; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; McNeal T; Ghamande S; Gibbs KW; Files DC; Hager DN; Ali H; Taghizadeh L; Gong MN; Mohamed A; Johnson NJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Khan A; Bender WS; Duggal A; Wilson JG; Qadir N; Chang SY; Mallow C; Kwon JH; Exline MC; Lauring AS; Shapiro NI; Columbus C; Halasa N; Chappell JD; Grijalva CG; Rice TW; Stubblefield WB; Baughman A; Womack KN; Rhoads JP; Hart KW; Swan SA; Lewis NM; McMorrow ML; Self WH;
    MMWR Morb Mortal Wkly Rep; 2022 Dec; 71(5152):1625-1630. PubMed ID: 36580424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines.
    He X; Su J; Ma Y; Zhang W; Tang S
    Front Immunol; 2022; 13():945930. PubMed ID: 36090988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022.
    Rosenblum HG; Wallace M; Godfrey M; Roper LE; Hall E; Fleming-Dutra KE; Link-Gelles R; Pilishvili T; Williams J; Moulia DL; Brooks O; Talbot HK; Lee GM; Bell BP; Daley MF; Meyer S; Oliver SE; Twentyman E
    MMWR Morb Mortal Wkly Rep; 2022 Nov; 71(45):1436-1441. PubMed ID: 36355612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study.
    Powell AA; Kirsebom F; Stowe J; Ramsay ME; Lopez-Bernal J; Andrews N; Ladhani SN
    Lancet Infect Dis; 2023 Apr; 23(4):435-444. PubMed ID: 36436536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination
    Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A mosaic-type trimeric RBD-based COVID-19 vaccine candidate induces potent neutralization against Omicron and other SARS-CoV-2 variants.
    Zhang J; Han ZB; Liang Y; Zhang XF; Jin YQ; Du LF; Shao S; Wang H; Hou JW; Xu K; Lei W; Lei ZH; Liu ZM; Zhang J; Hou YN; Liu N; Shen FJ; Wu JJ; Zheng X; Li XY; Li X; Huang WJ; Wu GZ; Su JG; Li QM
    Elife; 2022 Aug; 11():. PubMed ID: 36004719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine effectiveness and duration of protection of COVID-19 mRNA vaccines against Delta and Omicron BA.1 symptomatic and severe COVID-19 outcomes in adults aged 50 years and over in France.
    Tamandjou Tchuem CR; Auvigne V; Vaux S; Montagnat C; Paireau J; Monnier Besnard S; Gabet A; Benhajkassen N; Le Strat Y; Parent Du Chatelet I; Levy-Bruhl D
    Vaccine; 2023 Mar; 41(13):2280-2288. PubMed ID: 36870880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.